Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The Company has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.


TSXV:COV - Post by User

Bullboard Posts
Comment by bronkrdron May 09, 2020 1:37pm
156 Views
Post# 31007199

RE:RE:RE:RE:RE:RE:N95 Mask Re-use

RE:RE:RE:RE:RE:RE:N95 Mask Re-use
They were profits the previous two years and I would like to know the strategy and plans behind increasing the marketing and admin cost last year which dropped the bottom line by -$9M.
The sales were up but cost doubled in expeditures which might indicate long term returns and eventual increase in sales. What ever happened to the Saudi deal was before my investment in this company. I would like an update on this. If there was an increase in the sales force then CovaGuard should be a no brainer and other products should move as soon as elective surgeries jumps back in gear. I agree long term this is a winner. Stay safe.
Bullboard Posts